Therapy Areas: Cardiovascular
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
22 October 2024 - HELP Therapeutics Co. Ltd, a China-based clinical-stage cell therapy company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for it...
AstraZeneca's Wainzua recommended for EU approval
21 October 2024 - AstraZeneca PLC (LSE: AZN) (STO: AZN (Nasdaq: AZN) a global, science-led biopharmaceutical company, announced on Monday that Wainzua (eplontersen) has received a positive recommendat...
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
17 October 2024 - US-based global healthcare company Viatris Inc (Nasdaq:VTRS) announced on Wednesday that it has signed an exclusive licensing agreement with biopharmaceutical company Lexicon Pharmac...
AstraZeneca licenses Lp(a) asset from CSPC
7 October 2024 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Monday that it has entered into a licence agreement with CSPC Pharmaceutical Group Ltd (HKG:109...
Medinol completes First-in-Human implantation of ChampioNIR Drug-Eluting Peripheral Stent in Australia
7 October 2024 - Cardiovascular intervention company Medinol Ltd announced on Monday the successful First-in-Human implantation of its ChampioNIR Drug-Eluting Peripheral Stent by Drs Gerard S. Goh and...
Rivus Pharmaceuticals reveals new clinical data from HU6 Phase 2a HuMAIN study
1 October 2024 - Clinical-stage biopharmaceutical company Rivus Pharmaceuticals, Inc. announced on Monday positive results from its Phase 2a HuMAIN trial evaluating HU6 in patients with obesity-relate...